Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/48383
Title: Adequacy targets can be met in anuric patients by automated peritoneal dialysis: Baseline data from eapos
Authors: Brown, Edwina A.
Davies, Simon J.
Heimbürger, Olof
Meeus, Frederique
Mellotte, George
Rosman, Johan
Rutherford, Peter
Van Bree, Monique
Andres, E.
Borras, M.
Brown, E.
Caillette-Beaudoin, A.
Clutterbuck, E.
Davies, S.
D'Auzac, C.
Pompidou, G.
Ekstrand, A.
Frandsen, N. E.
Freida, P.
Kuypers, D.
Mactier, R.
MacNamara, E.
Malmsten, G.
Mastrangelo, F.
Perez-Contreras, J.
Riegel, W.
Rodrigues, A. S.
Rodriguez-Carmona, A.
Rosman, J.
Rutherford, P.
Scanziani, R.
Vega Diaz, N. 
Vychytil, A.
Weinreich, T.
UNESCO Clasification: 32 Ciencias médicas
3205 Medicina interna
Keywords: Anuria
Creatinine
Dialysis solutions
Peritoneal dialysis
Issue Date: 2001
Journal: Peritoneal Dialysis International 
Abstract: Objective: Conventional continuous ambulatory peritoneal dialysis (CAPD) in patients without residual renal function and with high solute transport is associated with worse clinical outcomes. Automated peritoneal dialysis (APD) has the potential to improve both solute clearance and ultrafiltration in these circumstances, but its efficacy as a treatment modality is unknown. The European Automated Peritoneal Dialysis Outcomes Study (EAPOS) is a 2-year, prospective, European multicenter study designed to determine APD feasibility and clinical outcomes in anuric patients. The present article describes the baseline data for patients recruited into the study. Design: All PD patients treated in the participating centers were screened for inclusion criteria [urinary output < 100 mL/24 h, or residual renal function (RRF) < 1 mL/min, or both]. After enrollment, changes were made to the dialysis prescription to achieve a weekly creatinine clearance above 60 L per 1.73 m2 and an ultrafiltration rate above 750 mL in 24 hours. Setting: The study is being conducted in 26 dialysis centers in 13 European countries. BASELINE DATA COLLECTION: The information collected includes patient demographics, dialysis prescription, achieved weekly creatinine clearance, and 24-hour ultrafiltration (UF). Results: The study enrolled 177 anuric patients. Median dialysis duration before enrollment was 22.5 months (range: 0-285 months). Mean solute transport measured as the dialysate-to-plasma ratio of creatinine (D/P(Cr)) was 0.74 +/- 0.12. Patients received APD for a median of 9.0 hours overnight (range: 7-12 hours) using a median of 11.0 L of fluid (range: 6-28.75 L). Median daytime volume was 4.0 L (range: 0.0-9.0 L). Tidal dialysis was used in 26 patients, and icodextrin in 86 patients. At baseline, before treatment optimization, the weekly mean total creatinine clearance was 65.2 +/- 14.4 L/1.73 m2, with 105 patients (60%) achieving the target of more than 60 L/1.73 m2. At baseline, 81% of patients with high transport, 69% with high-average transport, and 40% with low-average transport met the target. At baseline, 70% of patients with a body surface area (BSA) below 1.7 m2, 60% with a BSA of 1.7-2.0 m2, and 56% with a BSA above 2.0 m2 achieved 60 L/1.73 m2 weekly. Median UF was 1090 mL/24 h, and 75% of patients achieved the UF target of more than 750 mL/24 h. Conclusion: This baseline analysis of anuric patients recruited into the EAPOS study demonstrates that a high proportion of anuric patients on APD can achieve dialysis and ultrafiltration targets using a variety of regimes. This 2-year follow-up study aims to optimize APD prescription to reach predefined clearance and ultrafiltration targets, and to observe the resulting clinical outcomes.
URI: http://hdl.handle.net/10553/48383
ISSN: 0896-8608
Source: Peritoneal Dialysis International[ISSN 0896-8608],v. 21, sup. 3, pp. 133-137
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

32
checked on Nov 17, 2024

Page view(s)

76
checked on Sep 7, 2024

Google ScholarTM

Check


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.